DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
ONCOLOGY RESEARCH AND TREATMENT（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要